Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-659 + Venetoclax in Relapsed/Refractory NHL
NCT03357627Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Feb 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of mivavotinib in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (3 arms), sponsored by Calithera Biosciences. Primary endpoints: Number of Participants with a Dose Limiting Toxicity at 5 weeks and Percentage of Participants Reporting Treatment-emergent Adverse Events at 13 months. Started Feb 2018; status: completed.
02
Drugs
mivavotinib
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03357627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357627.